Jim Cramer rattles off his take on caller favorite stocks, including this play on food that many investors thought was safe to hide behind.» Read More
Iranian mischief is the single most bankable trend in the world, Cramer says. So he’s got a doomsday portfolio for you just in case events take a turn for the worst. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.
Boston Scientific's stock slid on Monday while shares of Abbott Laboratories jumped after a study showed Abbott's drug-coated stent was better at treating clogged heart arteries.
Sun Micro, Vodafone, Six Flags and more: Cramer tells you to buy or sell.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
In the second part of Cramer’s new series on non-pharma healthcare stocks, he sheds some light on this medical-imaging company.
Boston Scientific, saddled with debt and a depressed share price since buying Guidant last year, said on Monday it may sell a minority stake in its endosurgery business for more than $1 billion in a public offering.
Boston Scientific and Johnson & Johnson said on Monday that U.S. lawmakers have requested information from the companies on their drug-eluting stents to treat clogged heart arteries.
Today, Cramer tells callers what he thinks of Boston Scientific, Moody's, McDonald's, Noble Energy and more.
Boston Scientific's earnings came in a penny below estimates on higher expenses related to its acquisition of Guidant.
As I write this Pfizer shares are down about 2.5% in intra-day trading on top of the 1% loss yesterday. Usually investors cheer when a company announces substantial cost cuts--10,000 jobs, as many as eight facility closures or sales, $1.5 billion-$2 billion in savings by the end of '08. Yesterday you could argue the move was simple selling on the news as the layoffs and cost cuts had been leaked a week ahead of the meeting. But today ...
After the market close yesterday Pfizer, in an SEC filing, revealed that ousted Chairman and CEO Hank McKinnell will walk away with nearly $200 million in pension benefits, deferred compensation and other cash and stock including more than $300,000 in unused vacation time. This is well above the pension benefits that had been reported earlier this year and includes money that had not previously been disclosed. A Pfizer spokesman says the company is honoring its legal obligation to meet the terms of McKinnell's employment contract which was signed in 2001--"a different time in the company's history," he said.
Sellers outnumbered buyers on Wall Street after multiple reports signaled a slowdown in economic growth. CNBC's "Closing Bell" team sorted through the details.
As The Stomach Turns: Ah, the pressure of producing breaking news. I’ve done it enough times, yet I always find the monthly Philadelphia Fed report nerve wracking...
Boston Scientific has landed an exclusive contract to provide drug-coated stents to the Cleveland Clinic, one of the nation's most prominent cardiology centers, CNBC pharmaceuticals reporter Mike Huckman has learned.
Within the last few hours CNBC's Pharmaceuticals Reporter Mike Huckman broke the news that Boston Scientific has locked up a huge account, but at what price?
For traders, Christmas came early this year. A strong U.S. jobs report Friday and a rebound in the U.S. dollar have kicked up a bit of a "Santa Claus rally" in the markets. And at least one analyst says there are more gifts under the tree. Phil Dow, director of equity strategy at RBC Dain Rauscher, wouldn’t be surprised if we saw an additional percent or two before the year is through.
As we've been writing--CNBC pharmaceuticals reporter Mike Huckman has been reporting from Gaithersburg, Md--where the U.S. Food and Drug Administration has convened a panel to decide the fate of drug-coated stents. Johnson & Johnson and Boston Scientific – the two major producers of stents – have been eagerly awaiting a decision.
Greetings from the Gaithersburg, Maryland Hilton! That's where the FDA is holding the advisory committee meeting on the safety of drug-coated stents. For less high-profile FDA meetings this hotel and the Holiday Inn across the street (the FDA alternates between them) are just fine. But for a big meeting like this one the venue is way too small.
Drug-coated stents that buttress the arteries are safe when used as directed, health advisers say, even though the risks they may pose to the majority of patients with the devices remains an open question
There's late word from CNBC's Mike Huckman. He reported in "Closing Bell' that the FDA stent conference came out in support of drug-coated stents. There had been concerns the drug-coated stents caused blood clots--and the metal stents did not. But the FDA says the proof is inconclusive.